Comments on: Bristol-Myers Squibb Receives Positive CHMP Opinion in the European Union for Nivolumab (Opdivo, Nivolumab BMS) for the Treatment of Advanced Squamous Non-Small Cell Lung Cancer in Previously-Treated Patients

Comments on: Bristol-Myers Squibb Receives Positive CHMP Opinion in the European Union for Nivolumab (Opdivo, Nivolumab BMS) for the Treatment of Advanced Squamous Non-Small Cell Lung Cancer in Previously-Treated Patients https://www.worldpharmatoday.com/press-releases/bristol-myers-squibb-receives-positive-chmp-opinion-in-the-european-union-for-nivolumab-opdivo-nivolumab-bms-for-the-treatment-of-advanced-squamous-non-small-cell-lung-cancer-in-previously-treated-pat/ Magazine for the C-level Pharma Executives Thu, 21 May 2015 18:30:00 +0000 hourly 1 https://wordpress.org/?v=6.9.4